Related Experiment Video
Updated: May 12, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
Published on: July 20, 2022
Calciphylaxis diagnosis, management and future directions: a comprehensive update on behalf of the European Renal
Sharon Huish1,2, Sacha Moore3,4, Carlo Alfieri5,6
1Department of Renal Dietetics, Royal Devon University Healthcare NHS Foundation Trust, and University of Exeter, Exeter, UK.
Insights
Calciphylaxis (calcific uraemic arteriolopathy) is a severe condition causing painful skin lesions in dialysis patients. Recent research explores its causes, diagnostic biomarkers, and promising new treatments, emphasizing a multidisciplinary approach.
Area of Science:
- Nephrology
- Dermatology
- Vascular Biology
Background:
- Calciphylaxis, or calcific uraemic arteriolopathy, is a rare, life-threatening condition primarily affecting dialysis patients.
- It presents as painful, necrotic skin lesions resulting from arteriolar calcification and thrombosis, leading to high morbidity and mortality.
- Diagnosis is often delayed due to misdiagnosis and a lack of specific diagnostic tests.
Purpose of the Study:
- To provide an update on the latest understanding of calciphylaxis pathogenesis, diagnostic approaches, and management strategies.
- To highlight recent advances and future research directions in the field.
- To emphasize the need for systematic evaluation of novel therapies and improved diagnostic tools.
Main Methods:
- Review of current literature and registry data on calciphylaxis pathogenesis, diagnosis, and treatment.
- Discussion of emerging biomarkers such as the calciprotein particle crystallization test (T50) and plasma pyrophosphate.
- Highlighting the Better Evidence and Translation for Calciphylaxis (BEAT-Calci) adaptive platform trial for systematic therapy evaluation.
Main Results:
- Pathophysiological mechanisms involve vascular smooth muscle cell osteogenic transformation, loss of calcification inhibitors, inflammation, and thrombosis.
- Sodium thiosulfate is commonly used, but evidence is limited; investigational therapies like SNF472 and INZ-701 show promise.
- National registries and adaptive trials like BEAT-Calci are crucial for data collection and therapy evaluation.
Conclusions:
- Management of calciphylaxis is complex, requiring a multifaceted, multidisciplinary team approach.
- Future research should focus on validating diagnostic criteria, prognostic tools, and patient-reported outcomes.
- Developing and systematically evaluating new therapies is essential for improving outcomes in this vulnerable patient population.
Abstract:
Calciphylaxis, or calcific uraemic arteriolopathy, is a rare and life-threatening condition predominantly affecting people receiving dialysis. Characterized by painful necrotic skin lesions due to arteriolar calcification and thrombosis, calciphylaxis is associated with high morbidity and mortality. Diagnosis is frequently delayed due to misdiagnosis and an absence of specific diagnostic tests. Current treatment approaches are largely based on registry data and small uncontrolled studies. This update brings together the latest understanding of calciphylaxis pathogenesis, diagnostic approaches and management, highlighting recent advances and future directions. Pathophysiological mechanisms include vascular smooth muscle cell osteogenic transformation, loss of endogenous calcification inhibitors (fetuin-A, matrix Gla protein, pyrophosphate), systemic inflammation and thrombosis. The potential prognostic role of biomarkers, including the calciprotein particle crystallization test (T50) and plasma pyrophosphate, are also discussed. Management remains complex, with no proven treatments. A multifaceted, and multi-professional team approach is fundamental. Sodium thiosulfate remains widely used despite the lack of trial evidence. Recent investigational therapies, including SNF472 and INZ-701, target key calcification pathways and offer promise. The Better Evidence and Translation for Calciphylaxis (BEAT-Calci) adaptive platform trial represents a landmark step in evaluating multiple therapies systematically. National registries remain vital for informing prevalence estimates and improving real-world outcome data. Looking ahead, future research should prioritize the development and validation of diagnostic criteria, and prognostic tools integrating clinical risk factors with biomarkers. In addition, we propose the routine inclusion of patient-reported experience measures in calciphylaxis studies to better capture treatment impact in this vulnerable population.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management

